Inclusion Criteria:

- Patients with histologically confirmed GIST

- Imatinib resistance (primary resistance with progression, or progression after
initial response). Resistance is defined as objective evidence of progression after
at least 4 weeks of treatment with imatinib.

- Imatinib therapy has been interrupted >7 days before study entry

- Metastatic disease confirmed histologically, cytologically or radiologically

- Presence of measurable tumor lesions as determined by RECIST criteria

- Age 18 years or older

- WHO performance status of 2 or less

- Blood neutrophil count (ANC) 1.5 x 10^9/L or higher

- Platelet count 100 x 10^9/L or higher

- Serum bilirubin 1.5 x ULN (upper limit of normal) or less

- Serum creatinine 2.0 x ULN or less

- Written informed consent obtained according to local guidelines

Exclusion Criteria:

- Patients who have received chemotherapy less than 4 weeks prior to entry into this
study or who have not recovered from side effects of such therapy

- Patients who have received a cumulative dose of doxorubicin >450 mg/m2 or epirubicin
800 mg/m2

- Patients who have received immunotherapy within 2 weeks or who have not recovered
from side effects of such therapy

- Patients who have received radiotherapy within 2 weeks or who have not recovered from
side effects of such therapy

- Major surgery within 2 weeks prior to entry into this study or patients who have not
recovered from side effects of such therapy

- Patients who have received investigational drugs within 4 weeks prior to entry into
this study or who have not recovered from side effects of such therapy

- Patients who are pregnant or breast feeding, or adults of reproductive potential not
employing an effective method of birth control

- Concurrent severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,
congestive cardiac failure, myocardial infarction within 6 months, poorly controlled
hypertension, history of labile hypertension, history of poor compliance with
antihypertensive regimen, chronic renal disease, or active uncontrolled infection)
which could compromise participation in the study

- Acute or chronic liver disease (e.g., hepatitis, cirrhosis)

- Confirmed diagnosis of HIV infection

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of PTK787/ZK222584 (e.g., ulcerative disease, uncontrolled
nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability
to swallow the capsules/tablets)

- Patients who are taking Coumadin (warfarin sodium); heparin is acceptable.

- Patients unwilling to, or unable to, comply with the protocol